EPURIS 20 MG
ISOTRETINOIN : 20 MG · DIN 02396998 · CIPHER PHARMACEUTICALS INC
Health Canada status: MARKETED
What is EPURIS?
EPURIS 20 MG contains ISOTRETINOIN : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02396998, held by CIPHER PHARMACEUTICALS INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 07-May-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is EPURIS used for?
Severe nodular and/or inflammatory acne, acne conglobata, and recalcitrant acne unresponsive to conventional first-line therapies.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02396998 |
|---|---|
| Brand name | EPURIS |
| Generic / active ingredient | ISOTRETINOIN : 20 MG |
| Manufacturer | CIPHER PHARMACEUTICALS INC |
| Strength | 20 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | D10BA01 ISOTRETINOIN |
| AHFS class | 84:92.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 07-May-2013 |
| Original market date | 2013-05-07 00:00:00 |
How is it administered?
Initial: 0.5 mg/kg daily for 2-4 weeks. Maintenance: 0.1 to 1 mg/kg daily (max 2 mg/kg). Take with food. Course: 12-16 weeks. Not interchangeable with other isotretinoin products.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section 11 was listed in TOC but text cut off). Typically 15-30°C.
How is it supplied?
10 mg, 20 mg, 30 mg, and 40 mg capsules in compliance packaging. Prescription limited to 30-day supply for females of childbearing potential.
Contraindications
Pregnancy, breastfeeding, hepatic/renal insufficiency, hypervitaminosis A, elevated blood lipids, use with tetracyclines, sensitivity to isotretinoin or ingredients (soybean oil).
Warnings and precautions
Teratogenicity (severe birth defects); Psychiatric (depression, suicide risk); Neurologic (pseudotumor cerebri); Monitoring of lipids and liver function required.
What can be used instead?
Other Canadian products sharing ATC code D10BA01 ISOTRETINOIN. 12 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ABSORICA LD | 16 MG | CAPSULE | SUN PHARMACEUTICAL INDUSTRIES LIMITED | MARKETED | DIN 02539055 |
| ABSORICA LD | 24 MG | CAPSULE | SUN PHARMACEUTICAL INDUSTRIES LIMITED | MARKETED | DIN 02539063 |
| ABSORICA LD | 32 MG | CAPSULE | SUN PHARMACEUTICAL INDUSTRIES LIMITED | MARKETED | DIN 02539071 |
| ABSORICA LD | 8 MG | CAPSULE | SUN PHARMACEUTICAL INDUSTRIES LIMITED | MARKETED | DIN 02539047 |
| ACCUTANE ROCHE | 10 MG | CAPSULE | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 00582344 |
| ACCUTANE ROCHE | 40 MG | CAPSULE | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 00582352 |
| CLARUS | 10 MG | CAPSULE | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02257955 |
| CLARUS | 40 MG | CAPSULE | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02257963 |
| EPURIS | 10 MG | CAPSULE | CIPHER PHARMACEUTICALS INC | MARKETED | DIN 02396971 |
| EPURIS | 30 MG | CAPSULE | CIPHER PHARMACEUTICALS INC | MARKETED | DIN 02397005 |
Who else supplies ISOTRETINOIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ISOTRETINOIN appears in 1539 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.